Drug Trial Radar · NCT03303521
A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.
Last checked: Nov 20, 2026Latest source record: Feb 20, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
196
Actual
Start
Dec 14, 2017
Primary completion
Nov 7, 2018
Study completion Nov 7, 2018
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 6, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of ZS in the treatment of hyperkalemia in patients on hemodialysis.
Conditions
- Hyperkalemia
Interventions
PlaceboDrug
Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) . Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
Sodium Zirconium Cyclosilicate (ZS)Drug
Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) . Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of RespondersTime frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks, starting after visit 11 and ending on visit 15, thus it comprises post-long inter-dialytic interval visits 12, 13, 14 and 15.
- Percentage of Responders When Accounting for Missing Central Laboratory Serum Potassium DataTime frame: Evaluation period runs over the last 4 weeks of the treatment period up to 8 weeks, starting after visit 11 and ending on visit 15, thus it comprises post-long inter-dialytic interval visits 12, 13, 14 and 15.
Locations
53 sites in 4 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Ontario, California
Research Site
San Dimas, California
Research Site
Whittier, California
Research Site
Kansas City, Missouri
Research Site
St Louis, Missouri
Research Site
Paterson, New Jersey
Research Site
Fresh Meadows, New York
Research Site
Great Neck, New York
Research Site
Ridgewood, New York
Research Site
The Bronx, New York
Research Site
East Providence, Rhode Island
Research Site
El Paso, Texas
Research Site
Houston, Texas
Research Site
Hamamatsu, Japan
Research Site
Kumamoto, Japan
Research Site
Miyagi-gun, Japan
Research Site
Nagano, Japan
Research Site
Niigata, Japan
Research Site
Ora-gun, Japan
Research Site
Osaka, Japan
Research Site
Sakaishi, Japan
Research Site
Sashima-gun, Japan
Research Site
Sendai, Japan
Research Site
Shinjuku-ku, Japan
Research Site
Toride-shi, Japan
Research Site
Tsukuba, Japan
Research Site
Wakayama, Japan
Research Site
Yachiyo-shi, Japan
Research Site
Yokosuka-shi, Japan
Research Site
Kemerovo, Russia
Research Site
Kolomna, Russia
Research Site
Moscow, Russia
Research Site
Novosibirsk, Russia
Research Site
Omsk, Russia
Research Site
Penza, Russia
Research Site
Podolsk, Russia
Research Site
Rostov-on-Don, Russia
Research Site
Saint Petersburg, Russia
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.